Quantcast
Last updated on April 17, 2014 at 8:59 EDT

Latest Transthyretin Stories

2014-04-07 12:32:53

SAN DIEGO, April 7, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a preclinical-stage RNA medicines company pursuing rare diseases, today announced its President & CEO, Joseph E. Payne, has been invited to present at the 13(th) Annual Needham Healthcare Conference 2014, being held April 8-9 at The Westin Grand Central Hotel in New York City. In addition to a corporate summary, Payne's presentation will provide new data on the targeted delivery of RNA to the liver and kidney,...

2014-03-27 08:33:06

- LUNAR TM technology for the delivery of RNA medicines to multiple target organs and tumors will be presented SAN DIEGO, March 27, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a next wave RNA medicines company pursuing orphan diseases, today announced that its president & CEO, Joseph E. Payne, has been invited to present at the 21(st) Annual BioCentury Future Leaders in the Biotech Industry Conference, being held on March 28, 2014. In addition to providing a corporate...

2014-03-10 08:28:30

- In Vivo Delivery of RNA Medicines to Multiple Tissues Utilizing its Proprietary LUNARTM Delivery Technology - SAN DIEGO, March 10, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing orphan diseases, today announced that it has been selected to present at BIO-Europe Spring Partnering Conference 2014, being held March 10-12 in Turin, Italy. In addition to providing an update on Arcturus' flagship program targeting transthyretin (TTR)-mediated...

2014-03-03 08:30:46

CARLSBAD, Calif., March 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of an open-label extension study of ISIS-TTR(Rx), which is being offered to those patients with familial amyloid polyneuropathy (FAP) who have completed dosing in the Phase 2/3 study of ISIS-TTR(Rx). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO ISIS-TTR(Rx) is...

2014-02-24 12:27:26

SAN DIEGO, Feb. 24, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing rare diseases, today announced it will present at BIOCOM's Global Life Science Partnering Conference being held on February 26 and 27, 2014 at the Lodge in Torrey Pines, La Jolla, California. In addition to providing an update on its flagship program targeting transthyretin (TTR)-mediated amyloidosis, Arcturus will present data for its proprietary LUNAR(TM) delivery...

2014-02-14 16:24:52

CARLSBAD, Calif., Feb. 14, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending ISIS-TTR(Rx) for designation as an orphan medicinal product for the treatment of ATTR-Amyloidosis to the European Commission (EC). The opinion will be subject to review by the EC, which ultimately grants the decision on orphan drug designation. ATTR-Amyloidosis, or TTR amyloidosis,...

2014-01-30 08:30:19

- Arcturus proprietary LUNAR(TM) delivery technology demonstrates exceptional potency in vivo, ED(50) of 0.020 mg/kg SAN DIEGO, Jan. 30, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc. today announced it will present a poster at the Keystone Symposia Conference on RNA Silencing held January 31- February 5, 2014 in Seattle, Washington. The Arcturus poster titled "Design of a Novel, Potent, and Safe RNA Therapeutic Platform Utilizing LUNAR(TM) Delivery Technology" (poster...

2014-01-13 04:21:08

New Preclinical Results in Non-Human Primates Demonstrate Significant and Sustained Reduction of Transthyretin Using its Proprietary LUNARTM Delivery Technology SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., an industry leader in RNA technologies, today announced its flagship program - an RNAi therapeutic targeting transthyretin (TTR)-mediated amyloidosis. Preclinical non-human primate data will be presented at the Biotech Showcase being held January 13, 2014...

2013-12-02 08:30:17

CARLSBAD, Calif., Dec. 2, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the ongoing Phase 2/3 study of ISIS-TTR(Rx) in patients with familial amyloid polyneuropathy (FAP). (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) ISIS-TTR(Rx) is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a...

2013-07-30 08:33:03

CARLSBAD, Calif., July 30, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from GlaxoSmithKline (NYSE: GSK) related to the advancement of the ongoing Phase 2/3 study of ISIS-TTR(Rx) in patients with familial amyloid polyneuropathy (FAP). ISIS-TTR(Rx) is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by...